- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 183 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| 22.05. | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 16 Million | 316 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 19.05. | Spago Nanomedical Publishes the Annual Report for 2025 | 315 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2025 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 18.05. | Spago Nanomedical Presents Tumorad Clinical Data at the International ANZSNM 2026 Conference | 240 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented... ► Artikel lesen | |
| 11.05. | Notice To Annual General Meeting of Spago Nanomedical AB | 218 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 11, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version prevails... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March 2026 | 326 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 22 (KSEK 338)The loss for the quarter amounted... ► Artikel lesen | |
| 06.05. | Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake | 310 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01... ► Artikel lesen | |
| 24.03. | Spago Nanomedical's Abstract on Tumorad Accepted for Presentation at Radiopharma Conference | 311 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 24, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) today announced that an abstract describing the ongoing Phase I/IIa clinical study... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 17.03. | Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation | 302 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical... ► Artikel lesen | |
| 10.03. | Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development | 341 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 10, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten Malmström... ► Artikel lesen | |
| 05.02. | Spago Nanomedical Year-End Report January-December, 2025 | 360 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617)The loss for the quarter... ► Artikel lesen | |
| 08.12.25 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026 | 335 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 24.11.25 | Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue | 354 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 07.11.25 | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 442 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.11.25 | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 257 | GlobeNewswire (Europe) | The board of directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or "the Company") has today published an information document in connection with the Company's new share issue with rights... ► Artikel lesen | |
| 03.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.11.2025 | 594 | Xetra Newsboard | Das Instrument GW3 SE0009155518 GAPWAVES AB CLASS B O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 03.11.2025 und ex Kapitalmassnahme am 04.11.2025 The instrument GW3 SE0009155518 GAPWAVES AB CLASS... ► Artikel lesen | |
| 29.10.25 | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad | 379 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.10.25 | Spago Nanomedical Interim Report January-September 2025 | 342 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 29, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 14 (KSEK 485)The loss for the quarter amounted... ► Artikel lesen | |
| 14.10.25 | Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01 | 289 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 14, 2025 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase... ► Artikel lesen | |
| 20.08.25 | Spago Nanomedical Interim Report January-June, 2025 | 392 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amounted... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 15,710 | 0,00 % | Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns | ||
| ERASCA | 13,820 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,790 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| EDGEWISE THERAPEUTICS | 40,290 | +0,07 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,820 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,815 | -2,62 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,100 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| TYRA BIOSCIENCES | 30,390 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| IMMUNOME | 20,780 | 0,00 % | Immunome: Phase-3-Studie zu Varegacestat zeigt hohe Wirksamkeit bei Desmoid-Tumoren | ||
| IMMUNOVANT | 32,830 | -0,09 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 99,29 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| JADE BIOSCIENCES | 18,625 | +0,19 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,510 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| CG ONCOLOGY | 59,25 | +0,03 % | CG Oncology, Inc. - 8-K, Current Report |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.